Abstract
MAB-T88 is a human monoclonal IgM antibody directed at the lipopolysaccharide of gram-negative bacteria. A protocol was designed to identify a group of septic patients with a very high likelihood of gram-negative bacteremia. All 6 patients entered in the protocol had a gram-negative source, and 4 of 6 had gram-negative bacteremia. In this patient population, MAB-T88 was shown to be safe with an effective half-life of 19.1 hours.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 36-39 |
| Number of pages | 4 |
| Journal | Human Antibodies and Hybridomas |
| Volume | 4 |
| Issue number | 1 |
| State | Published - 1993 |
| Externally published | Yes |
ASJC Scopus subject areas
- Immunology
Fingerprint Dive into the research topics of 'Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis'. Together they form a unique fingerprint.
Cite this
Daifuku, R., Panacek, E. A., Haenftling, K., Swenson, W. K., Prescott, A. W., & Johnson, J. L. (1993). Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis. Human Antibodies and Hybridomas, 4(1), 36-39.